Principia Biopharma acquired by Sanofi for $3.7BN

Notable

Aug 17

Written By Frances Benson

2020

Frances Benson

Early interim data from Trident-1, a registrational Phase 2 of Repotrectinib

Pandion Therapeutics prices $135M IPO